CLDN5 and schizophrenia: Since 5-HT1A functions as a target for schizophrenia [22,26,43], further studies are required to determine whether 5-HT1A-targeting drugs improve the localized PKA activation and endothelial CLDN5 loss in schizophrenia in future experiments.